Streetbeat News

Equity Actions

SLGC

Madryn Asset Management, a significant shareholder of SomaLogic, has publicly opposed the proposed acquisition of Standard BioTools by SomaLogic. Madryn believes the transaction is not in the best interests of shareholders and has urged them to vote against it. The firm criticizes the deal's strategic rationale, financial terms, and potential impact on SomaLogic's future.

Portfolio Pulse from Bill Haddad

January 04, 2024 | 7:26 pm

ATAI

GHRS

Atai Life Sciences (NASDAQ:ATAI) has invested $50 million in Beckley Psytech Ltd. for the development of short-duration psychedelics for neuropsychiatric conditions. Atai now owns 35.5% of Beckley Psytech, which remains independent. The investment will accelerate the development of Beckley's psychedelic candidates, BPL-003 and ELE-101, with clinical trial results expected between H1 2024 and H2 2024. Atai's management believes in the potential of short-duration psychedelics to increase patient access and is building a large portfolio of psychedelic compounds. The collaboration may also explore digital tools for patient support and commercialization. GH Research (NASDAQ:GHRS) is also working with 5-MeO-DMT but is currently on clinical hold in the U.S.

Portfolio Pulse from Lara Goldstein

January 04, 2024 | 7:17 pm

EDR

There was a notable options market activity for Endeavor Group Holdings, with a sweep of 6,836 contracts for February 16 $26 calls, traded above the ask price at $0.4 per contract. This activity comes ahead of the company's earnings report, which is expected to be released after market close on February 27. The stock reference price at the time of the options trade was $23.255.

Portfolio Pulse from Charles Gross

January 04, 2024 | 7:02 pm

ZS

Options trading activity for Zscaler (NASDAQ:ZS) indicates a bearish sentiment among financial giants, with 61% of the unusual trades being bearish. The trades include 9 puts and 12 calls, with a focus on strike prices between $160 and $270. Zscaler, a SaaS cybersecurity firm, is currently trading at $211.19 with a slight increase of 0.45% and may be approaching overbought territory. The next earnings release is expected in 56 days.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 7:01 pm

RJF

Raymond James Finl (NYSE:RJF) received mixed analyst ratings in the last three months, with 1 bullish and 3 indifferent ratings. The average 12-month price target is $113.75, a decrease from the previous $119.00. Analysts from TD Cowen, Goldman Sachs, Morgan Stanley, and Jefferies have provided ratings and adjusted price targets. Raymond James Financial is a financial holding company with over $1 trillion assets under administration, with 90% of revenue from the U.S. and 70% from wealth management. The company's financial performance shows strong net margin and ROE, but revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 7:00 pm

TPG

Four analysts have recently updated their ratings on TPG Inc (NASDAQ:TPG), with a mix of bullish and indifferent stances. The average 12-month price target is now $37.75, up from the previous $32.00. Analysts from TD Cowen, Goldman Sachs, Deutsche Bank, and Morgan Stanley have provided ratings and price targets, with some raising their estimates. TPG's financial performance shows challenges in revenue growth, profitability, and debt management, with key metrics below industry standards.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 7:00 pm

PKX

POSCO Holdings Inc. (NYSE:PKX) stock has risen by 1.11% in the current session to $90.97, with a 3.93% increase over the past month and a 55.14% increase over the past year. The company's P/E ratio of 28.28 is higher than the Metals & Mining industry average of 14.6, which could suggest that the stock is overvalued or expected to perform better than its industry peers.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 6:30 pm

VC

Visteon (NASDAQ:VC), an automotive supplier, has been rated by 4 analysts over the past three months with mixed opinions. The average 12-month price target is $142.75, with a high of $149.00 and a low of $130.00, marking a 6.7% decrease from the previous average. Analysts from Exane BNP Paribas and Citigroup have given neutral and buy ratings, respectively, with Citigroup and UBS adjusting their price targets downward. Visteon's financials show a revenue decline of -1.17% over 3 months, a net margin of 6.51%, an ROE of 9.24%, an ROA of 2.82%, and a debt-to-equity ratio of 0.63.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 6:01 pm

MDB

MongoDB (NASDAQ:MDB) has been evaluated by 13 analysts over the last three months, with a mix of bullish to bearish sentiments. The average 12-month price target is $446.92, with a high of $500.00 and a low of $335.00. Recent actions by analysts include both raised and lowered price targets and ratings, reflecting changes in market dynamics and company performance. MongoDB's financials show a market cap above industry averages, a revenue growth rate of 29.77%, a net margin of -6.77%, an ROE of -3.16%, an ROA of -1.1%, and a debt-to-equity ratio of 1.22.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 6:00 pm

FIVE

Over the past three months, 10 analysts have provided diverse ratings for Five Below (NASDAQ:FIVE), with a shift towards more bullish sentiment in the last 30 days. The average 12-month price target has risen to $221.9, up 6.05% from the previous target. Analysts from firms like Barclays, Evercore ISI Group, Truist Securities, JP Morgan, Morgan Stanley, Wells Fargo, Citigroup, and Telsey Advisory Group have raised their price targets, indicating a positive outlook on the company's performance. Five Below, a value-oriented retailer, has shown strong financials with a market cap above industry average, revenue growth of 14.17%, high net margin, ROE, and ROA, and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 6:00 pm